131 related articles for article (PubMed ID: 32798788)
21. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
22. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
23. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
24. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
[TBL] [Abstract][Full Text] [Related]
25. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
27. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
[TBL] [Abstract][Full Text] [Related]
28. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
29. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
32. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
[TBL] [Abstract][Full Text] [Related]
33. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
34. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in B-RAF inhibitors as anticancer agents.
Khan PS; Rajesh P; Rajendra P; Chaskar MG; Rohidas A; Jaiprakash S
Bioorg Chem; 2022 Mar; 120():105597. PubMed ID: 35033817
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib.
Garbe C; Eigentler TK
Recent Results Cancer Res; 2018; 211():77-89. PubMed ID: 30069761
[TBL] [Abstract][Full Text] [Related]
37. Is B-Raf a good therapeutic target for melanoma and other malignancies?
Madhunapantula SV; Robertson GP
Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
[TBL] [Abstract][Full Text] [Related]
38. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT; Lee CH
J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
[TBL] [Abstract][Full Text] [Related]
39. Abrogation of B-Raf
Choi YW; Nam GE; Kim YH; Yoon JE; Park JH; Kim JH; Kang SY; Park TJ
Biochem Biophys Res Commun; 2019 Aug; 516(3):866-871. PubMed ID: 31270027
[TBL] [Abstract][Full Text] [Related]
40. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
